- Concept of molecular imaging
- Role of Cerianna PET in estrogen receptor–targeted molecular imaging
- Clinical applications of Cerianna PET that may improve patient care
Gary Ulaner, MD, PhD, FACNMJames & Pamela Muzzy Endowed Chair in Molecular Imaging and Therapy
Hoag Family Cancer Institute
Important Safety Information for Cerianna™ (fluoroestradiol F 18) Injection:
Limitations of Use - Tissue biopsy should be used to confirm recurrence of breast cancer and to verify ER status by pathology. CERIANNA is not useful for imaging other receptors, such as human epidermal growth factor receptor 2 (HER2) and the progesterone receptor (PR).
CONTRAINDICATIONS - None.
ADVERSE REACTIONS - In Clinical Trials (n=1207) the most common adverse reactions seen occurred at a rate <1% were injection-site pain and dysgeusia.
To report SUSPECTED ADVERSE REACTIONS, contact Zionexa US Corp, a GE Healthcare Company, at +1-844-946-6392, or the FDA at 1-800-FDA-1088, or www.fda.gov/medwatch.
For full Prescribing Information click here or visit cerianna.com/pi.
